MovDisordV3, PascalFrancis, Corpus, bibRecord, 002649

DA agonists: Ergot derivatives: Cabergoline

Identifieur interne : 002649 ( PascalFrancis/Corpus ); précédent : 002648; suivant : 002650

DA agonists: Ergot derivatives: Cabergoline

Auteurs :

Source :

Movement disorders [ 0885-3185 ] ; 2002.

RBID : Pascal:02-0472052

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Parkinsonisme, Médecine factuelle, Cabergoline, Chimiothérapie, Antiparkinsonien, Agoniste, Stimulant dopaminergique, Récepteur dopaminergique, Essai clinique, Trouble moteur, Complication, Traitement, Article synthèse, Toxicité, Homme, Prévention, Ergot dérivé.

English descriptors

KwdEn :
- Agonist, Antiparkinson agent, Cabergoline, Chemotherapy, Clinical trial, Complication, Dopamine agonist, Dopamine receptor, Ergot derivatives, Evidence-based medicine, Human, Motor system disorder, Parkinson disease, Parkinsonism, Prevention, Review, Toxicity, Treatment.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 17`
A06				`@3 SUP4`
A08	`01`	`1`	`ENG`	`@1 DA agonists: Ergot derivatives: Cabergoline`
A09	`01`	`1`	`ENG`	`@1 Management of Parkinson's disease: an evidence-based review`
A12	`01`	`1`		`@1 GOETZ (C. G.)`
A12	`02`	`1`		`@1 KOLLER (W. C.)`
A12	`03`	`1`		`@1 POEWE (W.)`
A12	`04`	`1`		`@1 RASCOL (O.)`
A12	`05`	`1`		`@1 SAMPAIO (C.)`
A12	`06`	`1`		`@1 BRIN (M. F.)`
A12	`07`	`1`		`@1 LEES (A. J.)`
A12	`08`	`1`		`@1 LEWITT (P.)`
A12	`09`	`1`		`@1 LOZANO (A.)`
A12	`10`	`1`		`@1 MIZUNO (Y.)`
A12	`11`	`1`		`@1 NUTT (J.)`
A12	`12`	`1`		`@1 OERTEL (W.)`
A12	`13`	`1`		`@1 OLANOW (C. W.)`
A12	`14`	`1`		`@1 TOLOSA (E.)`
A12	`15`	`1`		`@1 BREFEL-COURBON (C.)`
A12	`16`	`1`		`@1 EICHHORN (T.)`
A12	`17`	`1`		`@1 FERREIRA (J.)`
A12	`18`	`1`		`@1 KATZENSCHLAGER (R.)`
A12	`19`	`1`		`@1 LUGINGER (E.)`
A12	`20`	`1`		`@1 PASTOR (P.)`
A12	`21`	`1`		`@1 SEPPI (K.)`
A12	`22`	`1`		`@1 SPIEKER (S.)`
A12	`23`	`1`		`@1 PEARLMAN (S.)`
A18	`01`	`1`		`@1 Movement Disorder Society @2 Milwaukee, WI @3 USA`
A20				`@2 S68-S71`
A21				`@1 2002`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000108923890070`
A44				`@0 0000 @1 © 2002 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 02-0472052`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B06`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Parkinsonisme @2 NM @5 02`
C03	`02`	`X`	`ENG`	`@0 Parkinsonism @2 NM @5 02`
C03	`02`	`X`	`SPA`	`@0 Parkinson síndrome @2 NM @5 02`
C03	`03`	`X`	`FRE`	`@0 Médecine factuelle @5 04`
C03	`03`	`X`	`ENG`	`@0 Evidence-based medicine @5 04`
C03	`03`	`X`	`SPA`	`@0 Medicina basada en pruebas @5 04`
C03	`04`	`X`	`FRE`	`@0 Cabergoline @2 NK @2 FR @5 07`
C03	`04`	`X`	`ENG`	`@0 Cabergoline @2 NK @2 FR @5 07`
C03	`04`	`X`	`SPA`	`@0 Cabergolina @2 NK @2 FR @5 07`
C03	`05`	`X`	`FRE`	`@0 Chimiothérapie @5 08`
C03	`05`	`X`	`ENG`	`@0 Chemotherapy @5 08`
C03	`05`	`X`	`SPA`	`@0 Quimioterapia @5 08`
C03	`06`	`X`	`FRE`	`@0 Antiparkinsonien @5 09`
C03	`06`	`X`	`ENG`	`@0 Antiparkinson agent @5 09`
C03	`06`	`X`	`SPA`	`@0 Antiparkinsoniano @5 09`
C03	`07`	`X`	`FRE`	`@0 Agoniste @5 10`
C03	`07`	`X`	`ENG`	`@0 Agonist @5 10`
C03	`07`	`X`	`SPA`	`@0 Agonista @5 10`
C03	`08`	`X`	`FRE`	`@0 Stimulant dopaminergique @5 11`
C03	`08`	`X`	`ENG`	`@0 Dopamine agonist @5 11`
C03	`08`	`X`	`SPA`	`@0 Estimulante dopaminérgico @5 11`
C03	`09`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 12`
C03	`09`	`X`	`ENG`	`@0 Dopamine receptor @5 12`
C03	`09`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 12`
C03	`10`	`X`	`FRE`	`@0 Essai clinique @5 13`
C03	`10`	`X`	`ENG`	`@0 Clinical trial @5 13`
C03	`10`	`X`	`SPA`	`@0 Ensayo clínico @5 13`
C03	`11`	`X`	`FRE`	`@0 Trouble moteur @5 14`
C03	`11`	`X`	`ENG`	`@0 Motor system disorder @5 14`
C03	`11`	`X`	`SPA`	`@0 Trastorno motor @5 14`
C03	`12`	`X`	`FRE`	`@0 Complication @5 16`
C03	`12`	`X`	`ENG`	`@0 Complication @5 16`
C03	`12`	`X`	`SPA`	`@0 Complicación @5 16`
C03	`13`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`13`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`13`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`14`	`X`	`FRE`	`@0 Article synthèse @5 18`
C03	`14`	`X`	`ENG`	`@0 Review @5 18`
C03	`14`	`X`	`SPA`	`@0 Artículo síntesis @5 18`
C03	`15`	`X`	`FRE`	`@0 Toxicité @5 19`
C03	`15`	`X`	`ENG`	`@0 Toxicity @5 19`
C03	`15`	`X`	`SPA`	`@0 Toxicidad @5 19`
C03	`16`	`X`	`FRE`	`@0 Homme @5 20`
C03	`16`	`X`	`ENG`	`@0 Human @5 20`
C03	`16`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`17`	`X`	`FRE`	`@0 Prévention @5 23`
C03	`17`	`X`	`ENG`	`@0 Prevention @5 23`
C03	`17`	`X`	`SPA`	`@0 Prevención @5 23`
C03	`18`	`X`	`FRE`	`@0 Ergot dérivé @5 29`
C03	`18`	`X`	`ENG`	`@0 Ergot derivatives @5 29`
C03	`18`	`X`	`SPA`	`@0 Ergot derivado @5 29`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 42`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 42`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 42`
N21				`@1 273`
N82				`@1 PSI`

Format Inist (serveur)

NO :	PASCAL 02-0472052 INIST
ET :	DA agonists: Ergot derivatives: Cabergoline
AU :	GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.)
AF :	Movement Disorder Society/Milwaukee, WI/Etats-Unis
DT :	Publication en série; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S68-S71; Bibl. 26 ref.
LA :	Anglais
CC :	002B02B06
FD :	Parkinson maladie; Parkinsonisme; Médecine factuelle; Cabergoline; Chimiothérapie; Antiparkinsonien; Agoniste; Stimulant dopaminergique; Récepteur dopaminergique; Essai clinique; Trouble moteur; Complication; Traitement; Article synthèse; Toxicité; Homme; Prévention; Ergot dérivé
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique
ED :	Parkinson disease; Parkinsonism; Evidence-based medicine; Cabergoline; Chemotherapy; Antiparkinson agent; Agonist; Dopamine agonist; Dopamine receptor; Clinical trial; Motor system disorder; Complication; Treatment; Review; Toxicity; Human; Prevention; Ergot derivatives
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder
SD :	Parkinson enfermedad; Parkinson síndrome; Medicina basada en pruebas; Cabergolina; Quimioterapia; Antiparkinsoniano; Agonista; Estimulante dopaminérgico; Receptor dopaminérgico; Ensayo clínico; Trastorno motor; Complicación; Tratamiento; Artículo síntesis; Toxicidad; Hombre; Prevención; Ergot derivado
LO :	INIST-20953.354000108923890070
ID :	02-0472052

Links to Exploration step

Pascal:02-0472052

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">DA agonists: Ergot derivatives: Cabergoline</title>
<author><name sortKey="Goetz, C G" sort="Goetz, C G" uniqKey="Goetz C" first="C. G." last="Goetz">C. G. Goetz</name>
<affiliation><inist:fA14 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Koller, W C" sort="Koller, W C" uniqKey="Koller W" first="W. C." last="Koller">W. C. Koller</name>
</author>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name>
</author>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
</author>
<author><name sortKey="Sampaio, C" sort="Sampaio, C" uniqKey="Sampaio C" first="C." last="Sampaio">C. Sampaio</name>
</author>
<author><name sortKey="Brin, M F" sort="Brin, M F" uniqKey="Brin M" first="M. F." last="Brin">M. F. Brin</name>
</author>
<author><name sortKey="Lees, A J" sort="Lees, A J" uniqKey="Lees A" first="A. J." last="Lees">A. J. Lees</name>
</author>
<author><name sortKey="Lewitt, P" sort="Lewitt, P" uniqKey="Lewitt P" first="P." last="Lewitt">P. Lewitt</name>
</author>
<author><name sortKey="Lozano, A" sort="Lozano, A" uniqKey="Lozano A" first="A." last="Lozano">A. Lozano</name>
</author>
<author><name sortKey="Mizuno, Y" sort="Mizuno, Y" uniqKey="Mizuno Y" first="Y." last="Mizuno">Y. Mizuno</name>
</author>
<author><name sortKey="Nutt, J" sort="Nutt, J" uniqKey="Nutt J" first="J." last="Nutt">J. Nutt</name>
</author>
<author><name sortKey="Oertel, W" sort="Oertel, W" uniqKey="Oertel W" first="W." last="Oertel">W. Oertel</name>
</author>
<author><name sortKey="Olanow, C W" sort="Olanow, C W" uniqKey="Olanow C" first="C. W." last="Olanow">C. W. Olanow</name>
</author>
<author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
</author>
<author><name sortKey="Eichhorn, T" sort="Eichhorn, T" uniqKey="Eichhorn T" first="T." last="Eichhorn">T. Eichhorn</name>
</author>
<author><name sortKey="Ferreira, J" sort="Ferreira, J" uniqKey="Ferreira J" first="J." last="Ferreira">J. Ferreira</name>
</author>
<author><name sortKey="Katzenschlager, R" sort="Katzenschlager, R" uniqKey="Katzenschlager R" first="R." last="Katzenschlager">R. Katzenschlager</name>
</author>
<author><name sortKey="Luginger, E" sort="Luginger, E" uniqKey="Luginger E" first="E." last="Luginger">E. Luginger</name>
</author>
<author><name sortKey="Pastor, P" sort="Pastor, P" uniqKey="Pastor P" first="P." last="Pastor">P. Pastor</name>
</author>
<author><name sortKey="Seppi, K" sort="Seppi, K" uniqKey="Seppi K" first="K." last="Seppi">K. Seppi</name>
</author>
<author><name sortKey="Spieker, S" sort="Spieker, S" uniqKey="Spieker S" first="S." last="Spieker">S. Spieker</name>
</author>
<author><name sortKey="Pearlman, S" sort="Pearlman, S" uniqKey="Pearlman S" first="S." last="Pearlman">S. Pearlman</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">02-0472052</idno>
<date when="2002">2002</date>
<idno type="stanalyst">PASCAL 02-0472052 INIST</idno>
<idno type="RBID">Pascal:02-0472052</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002649</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">DA agonists: Ergot derivatives: Cabergoline</title>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2002">2002</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Cabergoline</term>
<term>Chemotherapy</term>
<term>Clinical trial</term>
<term>Complication</term>
<term>Dopamine agonist</term>
<term>Dopamine receptor</term>
<term>Ergot derivatives</term>
<term>Evidence-based medicine</term>
<term>Human</term>
<term>Motor system disorder</term>
<term>Parkinson disease</term>
<term>Parkinsonism</term>
<term>Prevention</term>
<term>Review</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Parkinsonisme</term>
<term>Médecine factuelle</term>
<term>Cabergoline</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Agoniste</term>
<term>Stimulant dopaminergique</term>
<term>Récepteur dopaminergique</term>
<term>Essai clinique</term>
<term>Trouble moteur</term>
<term>Complication</term>
<term>Traitement</term>
<term>Article synthèse</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Prévention</term>
<term>Ergot dérivé</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>17</s2>
</fA05>
<fA06><s3>SUP4</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>DA agonists: Ergot derivatives: Cabergoline</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Management of Parkinson's disease: an evidence-based review</s1>
</fA09>
<fA12 i1="01" i2="1"><s1>GOETZ (C. G.)</s1>
</fA12>
<fA12 i1="02" i2="1"><s1>KOLLER (W. C.)</s1>
</fA12>
<fA12 i1="03" i2="1"><s1>POEWE (W.)</s1>
</fA12>
<fA12 i1="04" i2="1"><s1>RASCOL (O.)</s1>
</fA12>
<fA12 i1="05" i2="1"><s1>SAMPAIO (C.)</s1>
</fA12>
<fA12 i1="06" i2="1"><s1>BRIN (M. F.)</s1>
</fA12>
<fA12 i1="07" i2="1"><s1>LEES (A. J.)</s1>
</fA12>
<fA12 i1="08" i2="1"><s1>LEWITT (P.)</s1>
</fA12>
<fA12 i1="09" i2="1"><s1>LOZANO (A.)</s1>
</fA12>
<fA12 i1="10" i2="1"><s1>MIZUNO (Y.)</s1>
</fA12>
<fA12 i1="11" i2="1"><s1>NUTT (J.)</s1>
</fA12>
<fA12 i1="12" i2="1"><s1>OERTEL (W.)</s1>
</fA12>
<fA12 i1="13" i2="1"><s1>OLANOW (C. W.)</s1>
</fA12>
<fA12 i1="14" i2="1"><s1>TOLOSA (E.)</s1>
</fA12>
<fA12 i1="15" i2="1"><s1>BREFEL-COURBON (C.)</s1>
</fA12>
<fA12 i1="16" i2="1"><s1>EICHHORN (T.)</s1>
</fA12>
<fA12 i1="17" i2="1"><s1>FERREIRA (J.)</s1>
</fA12>
<fA12 i1="18" i2="1"><s1>KATZENSCHLAGER (R.)</s1>
</fA12>
<fA12 i1="19" i2="1"><s1>LUGINGER (E.)</s1>
</fA12>
<fA12 i1="20" i2="1"><s1>PASTOR (P.)</s1>
</fA12>
<fA12 i1="21" i2="1"><s1>SEPPI (K.)</s1>
</fA12>
<fA12 i1="22" i2="1"><s1>SPIEKER (S.)</s1>
</fA12>
<fA12 i1="23" i2="1"><s1>PEARLMAN (S.)</s1>
</fA12>
<fA18 i1="01" i2="1"><s1>Movement Disorder Society</s1>
<s2>Milwaukee, WI</s2>
<s3>USA</s3>
</fA18>
<fA20><s2>S68-S71</s2>
</fA20>
<fA21><s1>2002</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000108923890070</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2002 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>02-0472052</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Parkinsonisme</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Parkinsonism</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Parkinson síndrome</s0>
<s2>NM</s2>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Médecine factuelle</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Evidence-based medicine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Medicina basada en pruebas</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cabergoline</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Cabergolina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Agonist</s0>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Agonista</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Stimulant dopaminergique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dopamine agonist</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Estimulante dopaminérgico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>12</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Essai clinique</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Clinical trial</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Ensayo clínico</s0>
<s5>13</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Trouble moteur</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Motor system disorder</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Trastorno motor</s0>
<s5>14</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Complication</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Complicación</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Article synthèse</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Review</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Artículo síntesis</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>19</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>19</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Prévention</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Prevention</s0>
<s5>23</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Prevención</s0>
<s5>23</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Ergot dérivé</s0>
<s5>29</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Ergot derivatives</s0>
<s5>29</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Ergot derivado</s0>
<s5>29</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>42</s5>
</fC07>
<fN21><s1>273</s1>
</fN21>
<fN82><s1>PSI</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 02-0472052 INIST</NO>
<ET>DA agonists: Ergot derivatives: Cabergoline</ET>
<AU>GOETZ (C. G.); KOLLER (W. C.); POEWE (W.); RASCOL (O.); SAMPAIO (C.); BRIN (M. F.); LEES (A. J.); LEWITT (P.); LOZANO (A.); MIZUNO (Y.); NUTT (J.); OERTEL (W.); OLANOW (C. W.); TOLOSA (E.); BREFEL-COURBON (C.); EICHHORN (T.); FERREIRA (J.); KATZENSCHLAGER (R.); LUGINGER (E.); PASTOR (P.); SEPPI (K.); SPIEKER (S.); PEARLMAN (S.)</AU>
<AF>Movement Disorder Society/Milwaukee, WI/Etats-Unis</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2002; Vol. 17; No. SUP4; S68-S71; Bibl. 26 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06</CC>
<FD>Parkinson maladie; Parkinsonisme; Médecine factuelle; Cabergoline; Chimiothérapie; Antiparkinsonien; Agoniste; Stimulant dopaminergique; Récepteur dopaminergique; Essai clinique; Trouble moteur; Complication; Traitement; Article synthèse; Toxicité; Homme; Prévention; Ergot dérivé</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative; Trouble neurologique</FG>
<ED>Parkinson disease; Parkinsonism; Evidence-based medicine; Cabergoline; Chemotherapy; Antiparkinson agent; Agonist; Dopamine agonist; Dopamine receptor; Clinical trial; Motor system disorder; Complication; Treatment; Review; Toxicity; Human; Prevention; Ergot derivatives</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Neurological disorder</EG>
<SD>Parkinson enfermedad; Parkinson síndrome; Medicina basada en pruebas; Cabergolina; Quimioterapia; Antiparkinsoniano; Agonista; Estimulante dopaminérgico; Receptor dopaminérgico; Ensayo clínico; Trastorno motor; Complicación; Tratamiento; Artículo síntesis; Toxicidad; Hombre; Prevención; Ergot derivado</SD>
<LO>INIST-20953.354000108923890070</LO>
<ID>02-0472052</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002649 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 002649 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:02-0472052
   |texte=   DA agonists: Ergot derivatives: Cabergoline
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

DA agonists: Ergot derivatives: Cabergoline

DA agonists: Ergot derivatives: Cabergoline

Source :

Descripteurs français

English descriptors

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri